Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Ecuador: These 14 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Ecuador: These 14 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

When can AMYVID (florbetapir f-18) generic drug versions launch?

Generic name: florbetapir f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2026
Generic Entry Controlled by: Ecuador Patent SP088783

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.

When can LASTACAFT (alcaftadine) generic drug versions launch?

Generic name: alcaftadine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 31, 2026
Generic Entry Controlled by: Ecuador Patent SP088786
Patent Title: TRATAMIENTOS DE LAS ALERGIAS OCULARES

LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.

When can TRADJENTA (linagliptin) generic drug versions launch?

Generic name: linagliptin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 04, 2026
Generic Entry Controlled by: Ecuador Patent SP088800

TRADJENTA is a drug marketed by Boehringer Ingelheim. There are eleven patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has four hundred and eighty-seven patent family members in forty-five countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Ecuador Patent SP088976

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Ecuador Patent SP088986

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

When can EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) generic drug versions launch?

Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Ecuador Patent SP088987

EXFORGE HCT is a drug marketed by Novartis.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering EXFORGE HCT

See drug price trends for EXFORGE HCT.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

When can BELSOMRA (suvorexant) generic drug versions launch?

Generic name: suvorexant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 01, 2026
Generic Entry Controlled by: Ecuador Patent SP099374

BELSOMRA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has seventy-five patent family members in thirty-six countries.

See drug price trends for BELSOMRA.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.

When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Ecuador Patent SP099489

INVOKAMET is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET

See drug price trends for INVOKAMET.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Ecuador Patent SP099489

INVOKAMET XR is a drug marketed by Janssen Pharms. There are four patents protecting this drug.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR

See drug price trends for INVOKAMET XR.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKANA (canagliflozin) generic drug versions launch?

Generic name: canagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Ecuador Patent SP099489

INVOKANA is a drug marketed by Janssen Pharms. There are four patents protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKANA

See drug price trends for INVOKANA.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the canagliflozin profile page.

When can BEVYXXA (betrixaban) generic drug versions launch?

Generic name: betrixaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Ecuador Patent SP099501
Patent Title: FORMULACIONES DE DOSIS UNITARIA Y MÉTODOS PARA EL TRATAMIENTO DE LA TROMBOSIS CON UN INHIBIDOR ORAL DEL FACTOR XA

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch?

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Ecuador Patent SP099413

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Ecuador Patent SP099608

OSENI is a drug marketed by Takeda Pharms Usa. There are four patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can KERENDIA (finerenone) generic drug versions launch?

Generic name: finerenone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 27, 2027
Generic Entry Controlled by: Ecuador Patent SP099581

KERENDIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug.

This drug has ninety-seven patent family members in forty-nine countries. There has been litigation on patents covering KERENDIA

See drug price trends for KERENDIA.

The generic ingredient in KERENDIA is finerenone. One supplier is listed for this generic product. Additional details are available on the finerenone profile page.

Last updated: December 27, 2025

Executive Summary

Ecuador's pharmaceutical sector presents a dynamic landscape, driven by socioeconomic factors, evolving healthcare policies, and regulatory frameworks. The market comprises both branded and generic drugs, with increasing emphasis on affordability and accessibility. Despite opportunities for growth, the sector faces challenges related to regulatory compliance, intellectual property rights, and market access.

This analysis explores Ecuador’s pharmaceutical market landscape, regulatory environment, and key opportunities and challenges for stakeholders. Emphasis is placed on identifying pathways for brand and generic drug companies, navigating regulatory reforms, and optimizing market entry strategies.

Market Overview: Ecuador’s Pharmaceutical Sector

Market Size and Growth

Indicator	Figures (2022/2023)	Notes
Total pharmaceutical market value	~$1.2 billion USD	Estimated, with a CAGR of 6% (2021-2026)
Branded drug market share	~65%	Dominates due to branding and patent protections
Generic drug market share	~35%	Growing segment driven by pricing and policy
Per capita healthcare expenditure	~$250 USD	Below Latin American average

Source: IMS Health, 2023; Ministry of Public Health Ecuador (MSP), 2022

Market Drivers

Demographic shifts: Aging population increases chronic disease prevalence.
Universal healthcare policies: Expansion under government programs like the Sistema Nacional de Salud.
Price sensitivity: Consumers and insurers favor generics to reduce costs.
Foreign investment: Increased interest from multinational pharmaceutical firms.

Market Segments

Segment	Approximate Market Share	Key Characteristics
Branded pharmaceuticals	65%	Patented, high marketing investment, premium pricing
Generic pharmaceuticals	35%	Cost-effective, growing due to regulatory shifts
OTC products	Unspecified	Significant due to self-medication trends

Regulatory Environment in Ecuador

Legal and Policy Framework

Pharmaceutical Law (Law No. 39, 2013): Sets standards for registration, manufacturing, and marketing of medicines.
Regulatory Authority: Agencia Nacional de Regulación, Control y Vigilancia de los Medicamentos, Alimentos y Bienes ese (ARCSA), later integrated into Agencia de Regulación y Control de la Seguridad Alimentaria y Adhesión a Normas (ARCSA).
Registration Process: Requires submission of technical dossiers, Good Manufacturing Practices (GMP) compliance, and safety/effectiveness data.
Patents and Intellectual Property: Ecuador complies with TRIPS, but enforcement for pharmaceuticals is limited, affecting generics.

Market Access and Drug Registration

Registration timeline: 6-12 months, depending on dossier completeness.
Data exclusivity: No explicit data exclusivity period for new medicines.
Generics: Allowed post-patent expiry; government supports for bioequivalent generics.
Price controls: Managed through Comisión Nacional de Precios de Medicamentos (Conamp); fixed or ceiling prices on essential medicines.

Key Regulatory Challenges

Issue	Description	Impact
Slow registration process	Bureaucratic delays inhibit timely market entry	Reduced competitiveness for new entrants
Limited patent enforcement	Weak intellectual property rights protection	Increased risk of patent infringement and counterfeit drugs
Price regulation	Price caps limit profitability, especially for innovative medicines	Discourages investment in R&D
Data requirements	Costly and complex dossier submission processes	Barrier for smaller manufacturers

Opportunities in Ecuador’s Pharma Markets

For Branded Drugs

Patent expiries and biosimilar opportunities: Several blockbuster patents expiring by 2025 open market for biosimilars and generics.
Partnerships with government programs: Participation in national procurement and public health initiatives.
Expanding disease indications: Focus on chronic diseases like diabetes and hypertension, which have increasing prevalence.

For Generic Drugs

Regulatory reforms favoring generics: Encouragement policies for bioequivalence documentation.
Cost-saving health policies: Government initiatives prioritize generics to reduce national drug expenditure.
Local manufacturing potential: Opportunity to establish or expand manufacturing facilities with local or regional integration.

Market Entry Strategies

Strategy	Description	Rationale
Strategic partnerships	Collaborate with local distributors or healthcare providers	Expedites market access and navigation of regulatory processes
Local manufacturing	Establish or partner with local facilities	Minimizes import tariffs, meets local content requirements
Value-added formulations	Develop combination drugs or formulations tailored to local needs	Differentiates offerings within price-sensitive markets

Key Challenges for Stakeholders

Regulatory and Market Barriers

Complex registration procedures often delay product launches.
Limited data exclusivity reduces incentives for innovative drug registration.
Price caps can constrain profitability and R&D investment.
Counterfeit risk and supply chain vulnerabilities threaten market integrity.

Intellectual Property Rights (IPR) Enforcement

Ecuador’s patent regime is underdeveloped, with the Patent Law not fully aligned with global standards.
Challenges remain in prosecuting patent infringements, discouraging innovation.

Market Competition and Local Dynamics

Presence of local producers offering lower-cost generics.
Pricing pressure from government agencies may limit profit margins.
Bureaucratic hurdles in licensing and customs clearance.

Comparison with Regional Markets

Aspect	Ecuador	Colombia	Peru	Brazil
Patent enforcement	Limited	Moderate	Moderate	Strong
Market size	~$1.2 billion USD	~$3.5 billion USD	~$1.6 billion USD	~$22 billion USD
Regulatory agency	ARCSA (now ARCSA)	INVIMA	DIGEMID	ANVISA
Generic market penetration	Growing, ~35%	Mature, high penetration	Growing	Mature, high penetration
Price control policies	Yes	Yes	Yes	Yes

Sources: IMS Health, 2023; OECD Reports, 2022; local agency websites.

Deep Dive: Opportunities vs. Challenges

Opportunities

Aspect	Potential Actions
Expiry of patents	Launch biosimilars, generics; fill patent voids
Government procurement policies	Engage in tenders, leverage cost-effective generics
Regulatory reforms	Capitalize on new pathways for faster approval
Local manufacturing	Reduce logistics costs, meet local content mandates

Challenges

Aspect	Mitigation Strategies
Regulatory delays	Build robust dossiers; engage with regulators proactively
Limited IPR enforcement	Invest in patent portfolios; legal counsel engagement
Pricing constraints	Focus on cost leadership; value-added products
Supply chain vulnerabilities	Diversify sourcing; strengthen quality controls

Conclusion & Key Takeaways

Ecuador offers a promising but complex environment for branded and generic drug companies. The market's expansion driven by demographic shifts, increased healthcare coverage, and a favorable regulatory opening provides opportunities for those attuned to local policies.

However, stakeholders must navigate regulatory delays, weak IPR frameworks, price controls, and supply chain risks. Strategic collaborations, local manufacturing, and compliance with evolving policies will be critical success factors.

Strategic recommendations include:

Engaging early with ARCSA to streamline registration processes.
Monitoring patent expiries to seize biosimilar and generic opportunities.
Building relationships with government agencies and local partners.
Investing in legal and regulatory expertise to manage IPR and compliance issues.
Aligning product offerings with local health priorities, especially chronic disease management.

FAQs

1. How does Ecuador's patent regime impact generic drug entry?
Ecuador's patent law offers limited data exclusivity, and enforcement mechanisms are weak, which can expedite generic market entry after patent expiry but may also lead to counterfeit proliferation and IPR issues. Companies should actively monitor patent statuses and engage with local legal counsel.

2. What are the primary regulatory hurdles for new drug registration?
The registration process can be protracted, often due to bureaucratic inefficiencies, incomplete dossiers, or stringent safety/effectiveness data requirements. Establishing local partnerships and engaging regulators proactively can mitigate delays.

3. How do government price controls influence market dynamics?
Price caps targeting essential medicines limit revenue streams, especially for innovative or branded drugs. This environment favors cost-effective generics and biosimilars but discourages R&D investment without additional incentives.

4. Are local manufacturing facilities advantageous in Ecuador?
Yes. Local production reduces import tariffs, consultancy in compliance, and supply chain complexities. It aligns with government preferences for local content and can enhance market competitiveness.

5. What industry sectors are poised for growth?
Biosimilars, chronic disease treatments (such as diabetes and hypertension), and OTC products are regions poised for growth, fueled by demographic trends and evolving healthcare policies.

References

IMS Health. (2023). Latin America Healthcare & Pharma Market Overview.
Ecuador Ministry of Public Health (MSP). (2022). Annual Health Sector Report.
OECD. (2022). Pharmaceutical Market Reports – Latin America.
Agencia Nacional de Regulación, Control y Vigilancia de los Medicamentos, Alimentos y Bienes (ARCSA). (2022). Regulatory Frameworks and Policies. (Now integrated into ARCSA’s new agency structure).

This comprehensive assessment aims to equip industry stakeholders with the insights necessary for strategic decision-making in Ecuador’s pharmaceutical sector.